Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer Annual Meeting
Fastmarkets Global Lithium, Battery & Critical Materials returns to Las Vegas as the key meeting point for deals, capital and supply chain strategy
Allied Critical Metals Announces Transformative U.S.$40 Million Financing Package to Fast-Track Tungsten Concentrates Production
Syntholene Energy Announces DTC Eligibility and Provides Update Regarding Investor Relations Activity
